Positive Media Coverage Somewhat Unlikely to Impact Catalyst Biosciences (CBIO) Stock Price
News articles about Catalyst Biosciences (NASDAQ:CBIO) have been trending positive this week, according to Accern. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catalyst Biosciences earned a daily sentiment score of 0.29 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.3194946010022 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Catalyst Biosciences (CBIO) On Phase 1/2 clinical trial evaluating subcutaneous administration of hemophilia B candidate CB 2679d/ISU304 – Slideshow (seekingalpha.com)
- Analysts Set $36.08 Price Target for Catalyst Biosciences Inc (CBIO) (americanbankingnews.com)
- Chardan Capital Boosts Catalyst Biosciences (CBIO) Price Target to $75.00 (americanbankingnews.com)
- Analyst Lifts Catalyst Biosciences PT From $10 To $75 On Hemophilia B Product (finance.yahoo.com)
- Catalyst Biosciences (CBIO) PT Set at $19.00 by B. Riley (americanbankingnews.com)
Shares of Catalyst Biosciences (NASDAQ CBIO) opened at $35.60 on Tuesday. The firm has a market capitalization of $186.91, a P/E ratio of -2.71 and a beta of 2.68. Catalyst Biosciences has a 52 week low of $3.11 and a 52 week high of $37.00.
WARNING: This piece of content was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/02/13/positive-media-coverage-somewhat-unlikely-to-impact-catalyst-biosciences-cbio-stock-price.html.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.